NeuroBo Pharmaceuticals, Inc. (NRBO)
- Previous Close
3.9600 - Open
4.0100 - Bid 2.8700 x 200
- Ask 5.0500 x 200
- Day's Range
3.9500 - 4.0999 - 52 Week Range
2.8880 - 6.7500 - Volume
5,541 - Avg. Volume
111,983 - Market Cap (intraday)
19.771M - Beta (5Y Monthly) -0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4600 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.67
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
www.neurobopharma.comRecent News: NRBO
Performance Overview: NRBO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRBO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRBO
Valuation Measures
Market Cap
19.77M
Enterprise Value
-2.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.18
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.26%
Return on Equity (ttm)
-64.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.47M
Diluted EPS (ttm)
-2.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
22.43M
Total Debt/Equity (mrq)
1.22%
Levered Free Cash Flow (ttm)
-15.55M
Research Analysis: NRBO
Company Insights: NRBO
NRBO does not have Company Insights